SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following news of a $400 million AI partnership with Perplexity, combined with a $500 million stock buyback program and positive Q3 earnings results. The community is discussing whether this marks a true turnaround for the stock, with some anticipating a short squeeze while others remain skeptical of the company's long-term profitability.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending downwards, with community members expressing concerns about recent performance despite a reported earnings beat. Discussions center around a distributor termination charge impacting EPS, as well as potential channel stuffing and inventory issues. Some investors view the dip as a buying opportunity, citing long-term growth potential and Pepsi's increased involvement, while others are losing faith.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its multi-year partnership with ESPN, making it the official sportsbook and odds provider. While some see this as a major catalyst for growth, others question its immediate impact given competition from prediction markets and potential earnings headwinds. Community discussions revolve around the deal's potential to boost market share and brand visibility versus concerns about management and overall market conditions.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix's stock is trending downwards as investors express frustration and distrust in management following repeated delays and missed deadlines, specifically regarding commercial smartphone production. The community is actively discussing the company's 2026 outlook, potential acquisitions, and the likelihood of securing purchase orders, with some expressing concern that competitors may catch up due to the delays, while others await CES for updates on smart eyewear products.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to investor frustration after earnings, with the community expressing disappointment over a lack of new partnerships and concerns about the CEO's strategy, especially regarding the CIC/Flu program. Many feel the company isn't prioritizing shareholder value, while others suggest a potential acquisition could be the best path forward amid skepticism about current management and execution.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending following a significant stock drop, despite positive earnings results and raised revenue guidance, sparking discussions about an overreaction. Community members are debating whether the dip presents a buying opportunity or if concerns about future growth and competition from AI are warranted, while analysts are weighing in with mixed opinions and price target adjustments.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors digest its latest earnings report, with some analysts raising price targets. Despite the positive outlook, the stock is experiencing volatility as the community debates whether the current valuation is justified and anticipates potential upgrades. Discussions also include the impact of prediction markets and potential partnerships.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending downwards as investors react negatively to news of a potential $250M ATM equity offering, sparking concerns about dilution and private equity influence. The stock's underperformance is fueling frustration, with community members citing management's perceived disregard for share price and questionable capital allocation. Despite revenue growth and long-term potential in the space sector, the market is expressing doubt in Redwire's execution and leadership.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending after a recent forecast disappointed some investors, leading to discussions about reduced full-year guidance and profitability. Despite the negative sentiment, some traders see this as a buying opportunity, referencing the stock's history of rebounding after similar drops. The community is actively debating the company's valuation, growth prospects, and the potential impact of tariffs.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending amid discussions about its recent performance and future potential, with some investors expressing disappointment over a recent sell-off despite strong revenue growth, while others see it as a buying opportunity. Community members are focused on the potential of RECORLEV to drive significant revenue and profitability in the coming years. Discussions also include speculation about potential buyout offers and the company's overall long-term prospects in the biopharmaceutical space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>It is now unclear when the company would apply for approval of the gene therapy, it said.</li><li>uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.&nbsp;</li><li>uniQure CEO termed the meeting outcome “unexpected.” &nbsp;</li></ul>uniQure N.V. (QURE) no longer believes that the U.S. Food and Drug Administration considers data from an early-to mid-stage trial of its investigational gene therapy for Huntington’s disease sufficient for approval, the company said on Monday.The company recently met with the agency, and although the minutes of the meeting have not been received, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179114/0/en/uniQure-Provides-Regulatory-Update-on-AMT-130-for-Huntington-s-Disease.html">believes</a> that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval.As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.<h2 class="st-heading-2">CEO Reacts</h2>uniQure CEO termed the meeting outcome “unexpected.”“We are surprised by the FDA’s feedback at the recent pre-BLA meeting, which is a drastic change from the guidance the FDA provided in November 2024 that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway,” CEO Matt Kapusta said.The company also stated that it intends to engage in further communications with other regulatory agencies while working with the FDA.<h2 class="st-heading-2">Expert Take</h2>Stifel analyst Annabel Samimy said that the news regarding the FDA's reversal on the approvability of uniQure's AMT-130 based on early to mid-stage trial data on the surface injects another layer of uncertainty into the workings of the FDA and their receptivity to gene therapy, more specifically.The analyst, however, does not expect this to impact Regenxbio’s (RGNX) rare disease programs. Meanwhile, Raymond James added that it does not expect the meeting outcome to impact Biohaven (BHVN) either.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>QURE stock traded 55% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.QURE stock is up 72% this year and approximately 445% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure Stock Tumbled 55% Today: What’s The FDA Angle?

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

Equity

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Mesoblast (MESO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorsmedia.mesoblast.com/static-files/45831458-f1fc-48e1-ae2c-ede16ee03af2">said</a> on Thursday it is awaiting the final minutes from the U.S. Food and Drug Administration (FDA) to provide timelines for potential filing for its late-stage product candidate Revascor. Nasdaq-listed shares of the company rose over 3% by Thursday morning.The biotechnology company is seeking to file an application for the approval of Revascor for the treatment of patients with ischemic chronic heart failure, characterized by an enlarged heart and insufficient blood flow to the organs and extremities of the body. The condition is estimated to affect 2% of the adult population of the United States.During the meeting held in the first week of June, there was general alignment on items regarding chemistry, manufacturing &amp; controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval, the company said.The firm added that it is now awaiting the final minutes from the FDA to determine the timeline for a potential approval filing.The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft versus host disease (SR-aGvHD). Ryoncil is currently approved for the treatment of pediatric patients two months of age and older, and the company is looking to expand the scope of its treatment to adults.On Stocktwits, retail sentiment around Mesoblast rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:634/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_10_45_51_AM_png_80e25b67b7.webp" alt="MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="634" height="63"><figcaption>MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the update from the company and said that it is at its “inflection point.”<stembedurl>https://stocktwits.com/Mani86/message/617651955</stembedurl><a href="https://stocktwits.com/symbol/MESO">MESO stock</a> is down by about 41% this year but up by nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cardinal-health-raises-fy25-earnings-guidance/chlgGvBRb6x">Cardinal Health’s Improved FY25 Earnings Guidance Draws Retail Cheer, Stock Inches Toward Record Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024.&nbsp;The healthcare technology company has surged from $35 to $53 in just three days, drawing significant retail attention.On Tuesday, Tempus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tempus-ai-stock-surges-on-ai-enabled-healthcare-app-launch-pelosi-buy/chbdxNURFV">introduced</a> an artificial intelligence-powered healthcare concierge app for patients, sparking optimism about its potential in the growing AI healthcare space.A routine stock trading disclosure revealed former House Speaker Nancy Pelosi purchased 50 call options on Tempus, expiring in January 2026 with a $20 strike price. This added to the speculative excitement surrounding the stock.President Donald Trump’s announcement of “Stargate,” a joint venture with OpenAI, Oracle, and SoftBank to invest billions in domestic AI development, further fueled investor enthusiasm for AI-related stocks like Tempus.While Tempus managed to see a 186% growth in retail followers on Stocktwits since Tuesday, sentiment shifted from ‘extremely bullish’ to ‘bearish’ by Thursday afternoon.&nbsp;The platform saw a spike in pessimistic messages, with users criticizing the frenzy over Pelosi’s involvement and some reporting profit-taking after the stock’s rally.<stembedurl>https://stocktwits.com/WallStreetBetzBoss/message/601130338</stembedurl><stembedurl>https://stocktwits.com/HIGHTABLETRADES/message/601134687</stembedurl><stembedurl>https://stocktwits.com/Harvz90/message/601192109</stembedurl>A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.&nbsp;That caused a brief dip in the stock earlier on Thursday, although it rebounded later in the session.Tempus AI has a short interest of 5.5%, according to Koyfin data.Shares of the company have gained over 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

Current Price	$26.54
Prev Close	$26.51
Open	$26.54
Dividend Yield	N/A
50-Day Moving Average	$24.87
Beta	N/A
Avg. Volume	14,921.09
PE Ratio	N/A

52-Week High	$26.76
52-Week Low	$17.84
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IBBQ
Invesco Nasdaq Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBBQ News

IBBQInvesco Nasdaq Biotechnology ETF